Haemonetics Corporation
HAE · NYSE
9/27/2025 | 6/28/2025 | 3/31/2025 | 12/28/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.05 | -0.66 | 0.24 | 1.91 |
| FCF Yield | 4.64% | 0.38% | 3.23% | 0.90% |
| EV / EBITDA | 55.06 | 57.47 | 40.63 | 54.57 |
| Quality | ||||
| ROIC | 2.01% | 1.86% | 2.69% | 1.94% |
| Gross Margin | 59.50% | 56.15% | 58.39% | 55.53% |
| Cash Conversion Ratio | 2.88 | 0.51 | 2.01 | 1.17 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.33% | 3.37% | 5.21% | 6.75% |
| Free Cash Flow Growth | 679.31% | -86.48% | 186.52% | -10.59% |
| Safety | ||||
| Net Debt / EBITDA | 15.87 | 11.95 | 9.22 | 10.27 |
| Interest Coverage | -8.12 | 13.54 | 119.29 | 6.48 |
| Efficiency | ||||
| Inventory Turnover | 0.39 | 0.39 | 0.38 | 0.43 |
| Cash Conversion Cycle | 243.30 | 257.08 | 250.25 | 226.97 |